🇺🇸 Rivastigmine patch in United States
32 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 32
Most-reported reactions
- Confusional State — 6 reports (18.75%)
- Fall — 5 reports (15.62%)
- Agitation — 3 reports (9.38%)
- Dyskinesia — 3 reports (9.38%)
- Mental Status Changes — 3 reports (9.38%)
- Tremor — 3 reports (9.38%)
- Urinary Tract Infection — 3 reports (9.38%)
- Blood Cholinesterase Decreased — 2 reports (6.25%)
- Cholinesterase Inhibition — 2 reports (6.25%)
- Constipation — 2 reports (6.25%)
Other Neurology approved in United States
Frequently asked questions
Is Rivastigmine patch approved in United States?
Rivastigmine patch does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Rivastigmine patch in United States?
Chung-Ang University Hosptial, Chung-Ang University College of Medicine is the originator. The local marketing authorisation holder may differ — check the official source linked above.